Gkb Ophthalmics Share Price
Sector: Medical Equipment & Supplies
74.97 -1.13 (-1.48%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
73.30
Today’s High
76.10
52 Week Low
59.00
52 Week High
131.75
Key Metrics
- Market Cap (In Cr) 37.84
- Beta 0.44
- Div. Yield (%) 0
- P/B 0.71
- TTM P/E -
- Sector P/E 40.98
- D/E 0
- Open Price 76.1
- Prev Close 76.1
Gkb Ophthalmics Analysis
Price Analysis
-
1 Week-0.42%
-
3 Months22.22%
-
6 Month-26.73%
-
YTD-25.32%
-
1 Year-26.62%
Risk Meter
- 53% Low risk
- 53% Moderate risk
- 53% Balanced Risk
- 53% High risk
- 53% Extreme risk
Gkb Ophthalmics News
GKB Ophthalmics Q1 results: loss at ₹0.25Cr, Revenue increased by 16.89% YoY
1 min read . 15 Aug 2024Gkb Ophthalmics Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 108.99
- Selling/ General/ Admin Expenses Total
- 17.26
- Depreciation/ Amortization
- 3.09
- Other Operating Expenses Total
- 21.07
- Total Operating Expense
- 114.86
- Operating Income
- -5.87
- Net Income Before Taxes
- -6.91
- Net Income
- -7.04
- Diluted Normalized EPS
- -13.98
- Period
- 2025
- Total Assets
- 125.21
- Total Liabilities
- 73.18
- Total Equity
- 52.04
- Tangible Book Valueper Share Common Eq
- 103.24
- Period
- 2025
- Cashfrom Operating Activities
- -3.43
- Cashfrom Investing Activities
- 2.55
- Cashfrom Financing Activities
- 0.67
- Net Changein Cash
- -0.21
- Period
- 2024
- Total Revenue
- 88.25
- Selling/ General/ Admin Expenses Total
- 13.76
- Depreciation/ Amortization
- 2.9
- Other Operating Expenses Total
- 14.18
- Total Operating Expense
- 90.57
- Operating Income
- -2.32
- Net Income Before Taxes
- -2.72
- Net Income
- -2.81
- Diluted Normalized EPS
- -5.63
- Period
- 2024
- Total Assets
- 114.5
- Total Liabilities
- 54.73
- Total Equity
- 59.77
- Tangible Book Valueper Share Common Eq
- 118.58
- Period
- 2024
- Cashfrom Operating Activities
- 4.22
- Cashfrom Investing Activities
- -1.71
- Cashfrom Financing Activities
- -1.64
- Net Changein Cash
- 0.87
- Period
- 2023
- Total Revenue
- 75.47
- Selling/ General/ Admin Expenses Total
- 11.15
- Depreciation/ Amortization
- 2.83
- Other Operating Expenses Total
- 13.23
- Total Operating Expense
- 74.62
- Operating Income
- 0.86
- Net Income Before Taxes
- 0.11
- Net Income
- -0.17
- Diluted Normalized EPS
- -0.42
- Period
- 2023
- Total Assets
- 112.27
- Total Liabilities
- 49.57
- Total Equity
- 62.69
- Tangible Book Valueper Share Common Eq
- 124.37
- Period
- 2023
- Cashfrom Operating Activities
- -2.77
- Cashfrom Investing Activities
- 1.43
- Cashfrom Financing Activities
- -2.19
- Net Changein Cash
- -3.53
- Period
- 2022
- Total Revenue
- 70.94
- Selling/ General/ Admin Expenses Total
- 9.49
- Depreciation/ Amortization
- 2.67
- Other Operating Expenses Total
- 11.75
- Total Operating Expense
- 68.76
- Operating Income
- 2.18
- Net Income Before Taxes
- 1.85
- Net Income
- 1.27
- Diluted Normalized EPS
- 2.53
- Period
- 2022
- Total Assets
- 110.16
- Total Liabilities
- 47.06
- Total Equity
- 63.1
- Tangible Book Valueper Share Common Eq
- 124.03
- Period
- 2022
- Cashfrom Operating Activities
- 5.07
- Cashfrom Investing Activities
- -3.52
- Cashfrom Financing Activities
- -1.66
- Net Changein Cash
- -0.12
- Period
- 2021
- Total Revenue
- 56.88
- Selling/ General/ Admin Expenses Total
- 7.86
- Depreciation/ Amortization
- 3.14
- Other Operating Expenses Total
- 10.04
- Total Operating Expense
- 58.82
- Operating Income
- -1.95
- Net Income Before Taxes
- -1.55
- Net Income
- -0.91
- Diluted Normalized EPS
- -0.87
- Period
- 2021
- Total Assets
- 106.82
- Total Liabilities
- 44.17
- Total Equity
- 62.65
- Tangible Book Valueper Share Common Eq
- 122.82
- Period
- 2021
- Cashfrom Operating Activities
- -3.66
- Cashfrom Investing Activities
- -6.26
- Cashfrom Financing Activities
- 2.77
- Net Changein Cash
- -7.15
- Period
- 2020
- Total Revenue
- 58.45
- Selling/ General/ Admin Expenses Total
- 8.1
- Depreciation/ Amortization
- 3.62
- Other Operating Expenses Total
- 11.19
- Total Operating Expense
- 60.02
- Operating Income
- -1.56
- Net Income Before Taxes
- -2.45
- Net Income
- -1.84
- Diluted Normalized EPS
- -3.67
- Period
- 2020
- Total Assets
- 102.25
- Total Liabilities
- 43
- Total Equity
- 59.25
- Tangible Book Valueper Share Common Eq
- 116.06
- Period
- 2020
- Cashfrom Operating Activities
- 3.27
- Cashfrom Investing Activities
- -3.73
- Cashfrom Financing Activities
- 4.3
- Net Changein Cash
- 3.84
- Period
- 2019
- Total Revenue
- 57.16
- Selling/ General/ Admin Expenses Total
- 9.27
- Depreciation/ Amortization
- 3.54
- Other Operating Expenses Total
- 11.17
- Total Operating Expense
- 59.55
- Operating Income
- -2.39
- Net Income Before Taxes
- -1.58
- Net Income
- -1.1
- Diluted Normalized EPS
- -4.39
- Period
- 2019
- Total Assets
- 93.43
- Total Liabilities
- 38.63
- Total Equity
- 54.81
- Tangible Book Valueper Share Common Eq
- 116.48
- Period
- 2019
- Cashfrom Operating Activities
- 3.92
- Cashfrom Investing Activities
- -9.89
- Cashfrom Financing Activities
- 13.13
- Net Changein Cash
- 7.16
- Period
- 2025-03-31
- Total Revenue
- 31.02
- Selling/ General/ Admin Expenses Total
- 4.54
- Depreciation/ Amortization
- 0.8
- Other Operating Expenses Total
- 6.83
- Total Operating Expense
- 34.68
- Operating Income
- -3.65
- Net Income Before Taxes
- -3.95
- Net Income
- -3.55
- Diluted Normalized EPS
- -7.03
- Period
- 2025-03-31
- Total Assets
- 125.21
- Total Liabilities
- 73.18
- Total Equity
- 52.04
- Tangible Book Valueper Share Common Eq
- 103.24
- Period
- 2025-03-31
- Cashfrom Operating Activities
- -3.43
- Cashfrom Investing Activities
- 2.55
- Cashfrom Financing Activities
- 0.67
- Net Changein Cash
- -0.21
- Period
- 2024-12-31
- Total Revenue
- 25.8
- Selling/ General/ Admin Expenses Total
- 4.29
- Depreciation/ Amortization
- 0.77
- Other Operating Expenses Total
- 6.05
- Total Operating Expense
- 27.48
- Operating Income
- -1.68
- Net Income Before Taxes
- -1.83
- Net Income
- -2.03
- Diluted Normalized EPS
- -4.03
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 26.14
- Selling/ General/ Admin Expenses Total
- 4.39
- Depreciation/ Amortization
- 0.77
- Other Operating Expenses Total
- 4.52
- Total Operating Expense
- 26.97
- Operating Income
- -0.82
- Net Income Before Taxes
- -1.15
- Net Income
- -1.22
- Diluted Normalized EPS
- -2.41
- Period
- 2024-09-30
- Total Assets
- 121.73
- Total Liabilities
- 63.55
- Total Equity
- 58.18
- Tangible Book Valueper Share Common Eq
- 115.43
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 0.36
- Cashfrom Investing Activities
- -1.14
- Cashfrom Financing Activities
- -0.25
- Net Changein Cash
- -1.02
- Period
- 2024-06-30
- Total Revenue
- 26.02
- Selling/ General/ Admin Expenses Total
- 4.04
- Depreciation/ Amortization
- 0.76
- Other Operating Expenses Total
- 3.68
- Total Operating Expense
- 25.73
- Operating Income
- 0.29
- Net Income Before Taxes
- 0.01
- Net Income
- -0.25
- Diluted Normalized EPS
- -0.5
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 21.56
- Selling/ General/ Admin Expenses Total
- 3.77
- Depreciation/ Amortization
- 0.72
- Other Operating Expenses Total
- 3.36
- Total Operating Expense
- 22.27
- Operating Income
- -0.71
- Net Income Before Taxes
- -0.79
- Net Income
- -0.91
- Diluted Normalized EPS
- -1.82
- Period
- 2024-03-31
- Total Assets
- 114.5
- Total Liabilities
- 54.73
- Total Equity
- 59.77
- Tangible Book Valueper Share Common Eq
- 118.58
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 4.22
- Cashfrom Investing Activities
- -1.71
- Cashfrom Financing Activities
- -1.64
- Net Changein Cash
- 0.87
- Period
- 2023-12-31
- Total Revenue
- 24.04
- Selling/ General/ Admin Expenses Total
- 3.67
- Depreciation/ Amortization
- 0.73
- Other Operating Expenses Total
- 3.38
- Total Operating Expense
- 25.26
- Operating Income
- -1.22
- Net Income Before Taxes
- -1.31
- Net Income
- -1.25
- Diluted Normalized EPS
- -2.48
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Gkb Ophthalmics Technical
Moving Average
SMA
- 5 Day75.9
- 10 Day75.68
- 20 Day75.93
- 50 Day73.71
- 100 Day76
- 300 Day89.54
Gkb Ophthalmics Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Alan Scott Industries
- 104
- 0.13
- 0.13
- 186.29
- 47.02
- 57.13
- Centenial Surgical Suture
- 147.1
- -1.55
- -1.04
- 169.5
- 82.15
- 53.66
- Gkb Ophthalmics
- 74.97
- -1.13
- -1.48
- 131.75
- 59
- 37.84
- Shree Pacetronix
- 74.4
- 0.39
- 0.53
- 245
- 61.11
- 26.46
- Adeshwar Meditex
- 18
- 0
- 0
- 27.5
- 15
- 25.98
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Alan Scott Industries
- -
- 29
- -72.98
- -15.92
- Centenial Surgical Suture
- -
- 1.76
- 1.4
- 0.9
- Gkb Ophthalmics
- -
- 0.74
- -3.18
- -2.4
- Shree Pacetronix
- 35.58
- 1.93
- 18.46
- 10.81
- Adeshwar Meditex
- 12.59
- 0.7
- 5.85
- 2.29
Gkb Ophthalmics Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 30-May-25
- Audited Results
- 13-Feb-25
- Quarterly Results
- 14-Nov-24
- Quarterly Results
- 13-Aug-24
- Quarterly Results
- 30-May-24
- Audited Results
- 14-Feb-24
- Quarterly Results
- 14-Nov-23
- Quarterly Results
- 11-Aug-23
- Quarterly Results
- 30-May-23
- Audited Results
- 14-Feb-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 20-Aug-24
- 05-Jun-24
- AGM
- 14-Sept-23
- 11-Aug-23
- AGM
- 12-Apr-22
- 11-Mar-22
- POM
- 28-Sept-21
- 11-Jun-21
- AGM



